Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza B virus vaccine (Symvivo)
- Development stage
- Preclinical
- Lead developer
- Symvivo
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Influenza B virus vaccine (Symvivo) is a preclinical-stage DNA vaccine candidate being developed by Symvivo Corporation for the prevention of Influenza B virus infection. The vaccine utilizes Symvivo's proprietary bacTRL™ platform technology, which employs genetically engineered probiotic bacteria (specifically *Bifidobacterium longum*) to deliver plasmid DNA encoding influenza B antigens. Administered either orally or intravenously, the platform enables the patient's own cells to express these antigens in vivo, thereby eliciting a targeted immune response. This approach combines elements of gene therapy and microbial therapy to provide a scalable and potentially more effective alternative to traditional influenza vaccines.
- Other names
- bacTRL Influenza B vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza B virus vaccine (Symvivo).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza B virus vaccine (Symvivo).